Botulinum toxin therapy for osteoarticular pain: An evidence-based review

Therapeutic Advances in Musculoskeletal Disease

Volumn 2, Issue 2, 2010, Pages 105-118

  Singh, Jasvinder A ^a  

^a VA MEDICAL CENTER   (United States)

Author keywords

arthritis; Botulinum toxin; pain; therapy

Indexed keywords

EID: 84993709337     PISSN: 1759720X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1759720X09357113     Document Type: Review

References (83)

1. Ahmed, M., Bjurholm, A., Schultzberg, M., Theodorsson, E. and Kreicbergs, A. ( 1995) Increased levels of substance P and calcitonin gene-related peptide in rat adjuvant arthritis. A combined immunohistochemical and radioimmunoassay analysis. Arthritis Rheum 38: 699-709.
2. Aoki, K.R. ( 2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(Suppl 1): S9-15.
3. Arnon, S.S., Schechter, R., Inglesby, T.V., Henderson, D.A., Bartlett, J.G., Ascher, M.S. et al. (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285: 1059-1070.
4. Babcock, M.S., Foster, L., Pasquina, P. and Jabbari, B. ( 2005) Treatment of pain attributed to plantar fasciitis with botulinum toxin A: a short-term, randomized, placebo-controlled, double-blind study. Am J Phys Med Rehabil 84: 649-654.
5. Bellamy, N., Campbell, J., Robinson, V., Gee, T., Bourne, R. and Wells, G. ( 2006a) Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev CD005328.
6. Bellamy, N., Campbell, J., Robinson, V., Gee, T., Bourne, R. and Wells, G. ( 2006b) Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev CD005321.
7. Birklein, F. and Schmelz, M. ( 2008) Neuropeptides, Neurogenic inflammation and complex regional pain syndrome (CRPS). Neurosci Lett 437: 199-202.
8. Bjork, M.A., Thyberg, I.S., Skogh, T. and Gerdle, B.U. ( 2007) Hand function and activity limitation according to health assessment questionnaire in patients with rheumatoid arthritis and healthy referents: 5-year followup of predictors of activity limitation (the Swedish Tira Project). J Rheumatol 34: 296-302.
9. Blersch, W., Schulte-Mattler, W.J., Przywara, S., May, A., Bigalke, H. and Wohlfarth, K. ( 2002) Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 205: 59-63.
10. Breivik, H., Collett, B., Ventafridda, V., Cohen, R. and Gallacher, D. ( 2006) Survey of chronic pain in europe: prevalence, impact on daily life, and treatment. Eur J Pain 10: 287-333.
11. Breuer, B., Sperber, K., Wallenstein, S., Kiprovski, K., Calapa, A., Snow, B. et al. (2006) Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpal tunnel syndrome. Pain Med 7: 16-24.
12. Centers for Disease Control and Prevention (CDC) ( 2009) Prevalence and most common causes of disability among adults-United States, 2005. MMWR Morb Mortal Wkly Rep 58: 421-426.
13. Cuevas-Trisan, R.L. and Cruz-Jimenez, M. ( 2006) The use of botulinum toxin in physical medicine and rehabilitation. Bol Asoc Med P R 98: 42-55.
14. Cui, M., Khanijou, S., Rubino, J. and Aoki, K.R. ( 2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107: 125-133.
15. Devillier, P., Weill, B., Renoux, M., Menkes, C. and Pradelles, P. ( 1986) Elevated levels of tachykinin-like immunoreactivity in joint fluids from patients with rheumatic inflammatory diseases. N Engl J Med 314: 1323.
16. Durham, P.L., Cady, R. and Cady, R. ( 2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44: 35-42, discussion 42-33.
17. Dykstra, D., Stuckey, M.W., Schimpff, S.N., Singh, J.A. and Mahowald, M.L. ( 2007) The effects of intra-articular botulinum toxin on sacroiliac, cervical/lumbar facet and sterno-calvicular joint pain and C-2 root and lumbar disc pain: a case series of 11 patients. The Pain Clinic 19: 27-32.
18. Feldmann, M. and Maini, S.R. ( 2008) Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 223: 7-19.
19. Foster, L., Clapp, L., Erickson, M. and Jabbari, B. ( 2001) Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 56: 1290-1293.
20. Freund, B. and Schwartz, M. ( 2003) Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain 4: 159-165.
21. Freund, B., Schwartz, M. and Symington, J.M. ( 2000) Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg 38: 466-471.
22. Ge, Z., Hu, Y., Heng, B.C., Yang, Z., Ouyang, H., Lee, E.H. et al. (2006) Osteoarthritis and therapy. Arthritis Rheum 55: 493-500.
23. Gobel, H., Heinze, A., Heinze-Kuhn, K. and Jost, W. ( 2001) Evidence based medicine: botulinum toxin A in migraine and tension type headache. J Neurol 248(Suppl): 34-38.
24. Green, S., Buchbinder, R., Glazier, R. and Forbes, A. ( 2003) Interventions for shoulder pain. Cochrane Database Syst Rev.
25. Hayton, M.J., Santini, A.J., Hughes, P.J., Frostick, S.P., Trail, I.A. and Stanley, J.K. ( 2005) Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. J Bone Joint Surg Am 87: 503-507.
26. Ho, K.Y. and Tan, K.H. ( 2007) Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review. Eur J Pain 11: 519-527.
27. Huijnen, B., van der Horst, F., van Amelsvoort, L., Wesseling, G., Lansbergen, M., Aarts, P. et al. (2006) Dyspnea in elderly family practice patients.
28. Occurrence, severity, quality of life and mortality over an 8-year period. Fam Pract 23: 34-39.
29. Hunter, D.J., McDougall, J.J. and Keefe, F.J. (2009) The symptoms of osteoarthritis and the genesis of pain. Med Clin North Am 93: 83-100, xi.
30. Jamtvedt, G., Dahm, K.T., Christie, A., Moe, R.H., Haavardsholm, E., Holm, I. et al. (2008) Physical therapy interventions for patients with osteoarthritis of the knee: an overview of systematic reviews. Phys Ther 88: 123-136.
31. Jankovic, J. and Schwartz, K. ( 1990) Botulinum toxin injections for cervical dystonia. Neurology 40: 277-280.
32. Jones, S.L. ( 1991) Descending noradrenergic influences on pain. Prog Brain Res 88: 381-394.
33. Kar, S., Gibson, S.J., Rees, R.G., Jura, W.G., Brewerton, D.A. and Polak, J.M. ( 1991) Increased calcitonin gene-related peptide (CGRP), substance P, and enkephalin immunoreactivities in dorsal spinal cord and loss of CGRP-immunoreactive motoneurons in arthritic rats depend on intact peripheral nerve supply. J Mol Neurosci 3: 7-18.
34. Keizer, S.B., Rutten, H.P., Pilot, P., Morre, H.H., V Os, J.J. and Verburg, A.D. ( 2002) Botulinum toxin injection versus surgical treatment for tennis elbow: a randomized pilot study. Clin Orthop Relat Res 125-131.
35. Kramer, H.H., Angerer, C., Erbguth, F., Schmelz, M. and Birklein, F. ( 2003) Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 250: 188-193.
36. Kvien, T.K. and Uhlig, T. ( 2005) Quality of life in rheumatoid arthritis. Scand J Rheumatol 34: 333-341.
37. Larsson, J., Ekblom, A., Henriksson, K., Lundeberg, T. and Theodorsson, E. ( 1991) Concentration of substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scand J Rheumatol 20: 326-335.
38. Lawrence, R.C., Helmick, C.G., Arnett, F.C., Deyo, R.A., Felson, D.T., Giannini, E.H. et al. (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41: 778-799.
39. Layeeque, R., Hochberg, J., Siegel, E., Kunkel, K., Kepple, J., Henry-Tillman, R.S. et al. (2004) Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Ann Surg 240: 608-613, discussion 613-614.
40. Lucioni, A., Bales, G.T., Lotan, T.L., McGehee, D.S., Cook, S.P. and Rapp, D.E. ( 2008) Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 101: 366-370.
41. Mahowald, M.L., Singh, J.A. and Dykstra, D. ( 2006) Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res 9: 179-188.
42. Meng, J., Wang, J., Lawrence, G. and Dolly, J.O. ( 2007) Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 120: 2864-2874.
43. Morre, H.H., Keizer, S.B. and van Os, J.J. ( 1997) Treatment of chronic tennis elbow with botulinum toxin. Lancet 349: 1746.
44. Neugebauer, V., Lucke, T. and Schaible, H.G. ( 1993) N-methyl-D-aspartate (NMDA) and non-NMDA receptor antagonists block the hyperexcitability of dorsal horn neurons during development of acute arthritis in rat's knee joint. J Neurophysiol 70: 1365-1377.
45. Ney, J.P., Difazio, M., Sichani, A., Monacci, W., Foster, L. and Jabbari, B. ( 2006) Treatment of chronic low back pain with successive injections of botulinum toxin A over 6 months: a prospective trial of 60 patients. Clin J Pain 22: 363-369.
46. Patti, R., Arcara, M., Bonventre, S., Sammartano, S., Sparacello, M., Vitello, G. et al. (2008) Randomized clinical trial of botulinum toxin injection for pain relief in patients with thrombosed external haemorrhoids. Br J Surg 95: 1339-1343.
47. Placzek, R., Deuretzbacher, G., Buttgereit, F. and Meiss, A.L. ( 2005) Treatment of chronic plantar fasciitis with botulinum toxin A: an open case series with a 1 year follow up. Ann Rheum Dis 64: 1659-1661.
48. Purkiss, J., Welch, M., Doward, S. and Foster, K. ( 2000) Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 59: 1403-1406.
49. Rains, C. and Bryson, H.M. ( 1995) Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging 7: 317-328.
50. Ranoux, D., Attal, N., Morain, F. and Bouhassira, D. ( 2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 64: 274-283.
51. Rapp, D.E., Turk, K.W., Bales, G.T. and Cook, S.P. ( 2006) Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175: 1138-1142.
52. Salaffi, F., Carotti, M., Stancati, A. and Grassi, W. ( 2005) Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging Clin Exp Res 17: 255-263.
53. Schaible, H.G., Schmidt, R.F. and Willis, W.D. ( 1987) Enhancement of the responses of ascending tract cells in the cat spinal cord by acute inflammation of the knee joint. Exp Brain Res 66: 489-499.
54. Schaible, H.G., Del Rosso, A. and Matucci-Cerinic, M. ( 2005) Neurogenic aspects of inflammation. Rheum Dis Clin North Am 31: 77-101, ix.
55. Schaible, H.G., Schmelz, M. and Tegeder, I. ( 2006) Pathophysiology and treatment of pain in joint disease. Adv Drug Deliv Rev 58: 323-342.
56. Schaible, H.G., Richter, F., Ebersberger, A., Boettger, M.K., Vanegas, H., Natura, G. et al. (2009) Joint pain. Exp Brain Res 196: 153-162.
57. Siddiqui, M.A. ( 2007) The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. Curr Opin Rheumatol 19: 308-313.
58. Singer, B.J., Silbert, P.L., Dunne, J.W., Song, S. and Singer, K.P. ( 2006) An open label pilot investigation of the efficacy of botulinum toxin type A [Dysport] injection in the rehabilitation of chronic anterior knee pain. Disabil Rehabil 28: 707-713.
59. Singh, J.A., Mahowald, M.L., Kushnaryov, A., Goelz, E. and Dykstra, D. (2009) Repeat Injections of intra-articular botulinum toxin A for the treatment of chronic arthritis joint pain. J Clin Rheumatol 15: 35-38.
60. Singh, J.A., Mahowald, M.L. and Noorbaloochi, S. ( 2009) Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res 153: 205-216.
61. Slatkowsky-Christensen, B., Mowinckel, P., Loge, J.H. and Kvien, T.K. ( 2007) Health-related quality of life in women with symptomatic hand osteoarthritis: a comparison with rheumatoid arthritis patients, healthy controls, and normative data. Arthritis Rheum 57: 1404-1409.
62. Sycha, T., Kranz, G., Auff, E. and Schnider, P. ( 2004) Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature. J Neurol 251(Suppl 1): 119-30.
63. Sycha, T., Samal, D., Chizh, B., Lehr, S., Gustorff, B., Schnider, P. et al. (2006) A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg 102: 509-516.
64. van der Windt, D.A. and Bouter, L.M. ( 2003) Physiotherapy or corticosteroid injection for shoulder pain? Ann Rheum Dis 62: 385-387.
65. Voller, B., Sycha, T., Gustorff, B., Schmetterer, L., Lehr, S., Eichler, H.G. et al. (2003) A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 61: 940-944.
66. von Lindern, J.J. ( 2001) Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction. Acta Neurol Belg 101: 39-41.
67. von Lindern, J.J., Niederhagen, B., Berge, S. and Appel, T. ( 2003) Type A botulinum toxin in the
68. treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg 61: 774-778.
69. Watkins, L.R. and Maier, S.F. ( 2002) Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 82: 981-1011.
70. Watkins, L.R. and Maier, S.F. ( 2003) Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2: 973-985.
71. Watkins, L.R., Milligan, E.D. and Maier, S.F. ( 2003) Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv Exp Med Biol 521: 1-21.
72. Willis, W.D. and Westlund, K.N. ( 1997) Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol 14: 2-31.
73. Wong, S.M., Hui, A.C., Tong, P.Y., Poon, D.W., Yu, E. and Wong, L.K. ( 2005) Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 143: 793-797.
74. Woolf, C.J. ( 2004) Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 140: 441-451.
75. Woolf, C.J. and Costigan, M. ( 1999) Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci U S A 96: 7723-7730.
76. Woolf, C.J. and Decosterd, I. ( 1999) Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain Suppl 6: S141-S147
77. Woolf, C.J. and Mannion, R.J. ( 1999) Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353: 1959-1964.
78. Woolf, C. and Wiesenfeld-Hallin, Z. ( 1986) Substance P and calcitonin gene-related peptide synergistically modulate the gain of the nociceptive flexor withdrawal reflex in the rat. Neurosci Lett 66: 226-230.
79. Woolf, C.J., Safieh-Garabedian, B., Ma, Q.P., Crilly, P. and Winter, J. ( 1994) Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 62: 327-331.
80. Woolf, C.J., Allchorne, A., Safieh-Garabedian, B. and Poole, S. ( 1997) Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 121: 417-424.
81. Yuan, R.Y., Sheu, J.J., Yu, J.M., Chen, W.T., Tseng, I.J., Chang, H.H. et al. (2009) Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 72: 1473-1478.
82. Zhang, W., Moskowitz, R.W., Nuki, G., Abramson, S., Altman, R.D., Arden, N. et al. (2007) Oarsi recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 15: 981-1000.
83. Zhang, W., Moskowitz, R.W., Nuki, G., Abramson, S., Altman, R.D., Arden, N. et al. (2008) Oarsi recommendations for the management of hip and knee osteoarthritis, part II: oarsi evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16: 137-162.